(Q43767729)

26 November 2017

Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women (English)

1 reference

26 November 2017

0 references

1 reference

Hua Bai

1

1 reference

26 November 2017

Danqing Jing

series ordinal

2

1 reference

26 November 2017

Aitao Guo

series ordinal

3

1 reference

26 November 2017

Shinan Yin

series ordinal

4

1 reference

26 November 2017

13 May 2013

1 reference

Journal of International Medical Research

26 November 2017

1 reference

26 November 2017

41

1 reference

26 November 2017

3

1 reference

26 November 2017

697-704

1 reference

Osteoporosis prevention, diagnosis, and therapy

26 November 2017

1 reference

https://api.crossref.org/works/10.1177%2F0300060513480917

Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0300060513480917

An economic evaluation: Simulation of the cost-effectiveness and cost-utility of universal prevention strategies against osteoporosis-related fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0300060513480917

Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacological osteoporosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0300060513480917

The effects of strontium ranelate in Asian women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0300060513480917

Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0300060513480917

Loss of treatment benefit due to low compliance with bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0300060513480917

Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0300060513480917

Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0300060513480917

Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0300060513480917

The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0300060513480917

Detecting early biomechanical effects of zoledronic Acid on femurs of osteoporotic female rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0300060513480917

Vertebral fracture assessment using a semiquantitative technique.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0300060513480917

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0300060513480917

The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0300060513480917

Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0300060513480917

Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0300060513480917

Fracture risk and zoledronic acid therapy in men with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0300060513480917

Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0300060513480917

Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0300060513480917

Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0300060513480917

21 January 2018

Identifiers

DOI

10.1177/0300060513480917

1 reference

26 November 2017

1 reference